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INTRODUCTION
Barrett’s esophagus (BE) is characterized by a change of the normal stratified squamous 
epithelium lining the esophagus to a metaplastic columnar epithelium with goblet cells. The 
prevalence of BE is estimated to be 1.5% in the general population [1, 2] and as high as 15% 
in those with gastroesophageal reflux disease (GERD) [3, 4]. Other risk factors associated 
with BE are older age, male sex, smoking, central obesity, and white race [5–10]. There also 
appears to be an increased genetic pre-disposition among those with first-degree relatives 
with BE [11].
BE is a known precursor to esophageal adenocarcinoma (EAC), and oncogenesis is thought 
to occur through a sequential progression from metaplasia to dysplasia to carcinoma. The 
risk of developing EAC is as high as 7% per year in those with high-grade dysplasia (HGD) 
[12] and 0.7% per year in low-grade dysplasia (LGD). However, reports of EAC risk in LGD 
are highly disparate, ranging from risks approximating that of non-dysplastic BE (NDBE), 
to risks of progression to HGD or EAC of 10% per year or more [8, 13–16]. EAC is 
associated with high mortality and is increasing in incidence in the western world [17–19]. 
Risk factors for progression of BE to EAC include increasing degree of dysplasia, increasing 
age, increasing BE segment length, male sex, and smoking, among others [20]. Therefore, 
there is a need to optimize screening, surveillance, and treatment of high-risk BE with the 
ultimate goal of decreasing the disease burden and mortality associated with EAC.
In this review article, we will briefly discuss the diagnostic criteria and endoscopic screening 
for BE. We will then review the indications and performance of endoscopic surveillance, 
with an emphasis on possible new directions to improve the performance of surveillance. We 
will conclude with a discussion of the management of BE, with an emphasis on the 
indications, technique, and outcomes of endoscopic therapy for BE.
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DIAGNOSIS
Diagnostic Criteria
Current guidelines recommend that the diagnosis of BE should be based on the presence of 
columnar epithelium ≥1 cm proximal to the gastroesophageal (GE) junction with biopsies 
consistent with intestinal metaplasia (IM) [8]. This is in contrast to British diagnostic 
criteria, where confirmation of IM is not required for diagnosis [21]. The relationship 
between the presence of IM and progression to EAC has been conflicting [22–24], and 
complicated both by sampling error [25] and interobserver variability among pathologists 
[26]. Studies have shown that there is a significant increase in the likelihood of finding IM 
with increasing number of biopsy samples taken during endoscopy [27].
As a result, the recommended number of random biopsy samples are 4 samples for every 2 
cm of BE segment length or 8 for segment length <2 cm in those with suspected BE [28]. In 
addition, a normal or mildly irregular Z-line should not be routinely biopsied because IM of 
the cardia is common in chronic GERD patients [29] and has not been definitively 
demonstrated to imply an increased risk of EAC [30, 31]. In terms of BE classification, a 
segment >3 cm is defined as long-segment BE and segment <3 cm as short-segment BE. The 
Prague classification [32] describing the circumferential and maximum extent of BE is used 
for standardized reporting, in addition to endoscopic landmarks such as the diaphragmatic 
hiatus, gastroesophageal junction, and the squamocolumnar junction [8].
Screening
The primary goal of screening is to identify patients with BE. However, the question of who 
to screen is complex, because >90% of patients who develop EAC have no prior history of 
BE, and the traditional practice of screening GERD patients misses a substantial group 
destined to develop EAC, because approximately 40% of EAC patients do not have a history 
of chronic GERD [33–35]. Despite these shortcomings, screening guidelines have 
traditionally focused on a sub-set that is at higher risk for BE and EAC, which include men 
with chronic GERD symptoms and 2 additional risk factors including age >50, white race, 
central obesity, smoking history, and family history [8]. Although risk-stratification models 
[36–38] have been developed to aid in determining who to screen for BE, these models need 
further validation and their role in clinical practice is currently limited.
The most commonly used screening modality for BE is conventional per oral upper 
endoscopy with biopsy samples from any endoscopically visible columnar mucosa in the 
tubular esophagus. Limitations of endoscopy for screening are that it is an invasive 
procedure requiring a specialist and that it is costly [39]. Brush cytology sampling might 
reduce cost, increase the surface area that can be analyzed, and be used in combination with 
molecular markers to aid in risk-stratification. Wide-area transepithelial sampling (WATS) 
uses computer-assisted analysis of an abrasive transepithelial brush biopsy to sample a larger 
surface area, to help overcome the issue of sampling error. When WATS is used in 
conjunction with 4-quadrant biopsies, there is on average a 40% incremental yield of 
dysplasia and metaplasia detection in 2 prospective trials [40, 41]. In addition, there is high 
interobserver agreement [42] for detection of not only BE (κ=0.88) and HGD/EAC 
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(κ=0.95), but also for LGD (κ=0.74), in contrast to the low inter-observer agreement with 
traditional 4-quadrant biopsies [43]. However, this technology is currently used as an adjunct 
to per oral endoscopy, meaning that costs associated with endoscopy are not avoided.
Alternative endoscopic techniques for screening include transnasal endoscopy (TNE), and 
single-fiber endoscopy. TNE uses a smaller-caliber scope and is inserted into the esophagus 
orally or nasally without the need for sedation [44]. TNE has been shown to be comparable 
to standard endoscopy for detection of BE and for the quality of biopsy specimens [45–47]. 
In addition, TNE is well tolerated and has demonstrated efficacy in a community setting [44, 
48, 49]. However, most gastroenterologists have limited experience with transnasal 
approaches, which require good nasopharyngeal anesthesia, and knowledge of pertinent 
landmarks. Endoscopes with a disposable sheath (EndoSheath; Vision Sciences, 
Orangeburg, NY) and disposable esophagoscopes (EG scan; IntroMedic, Seoul, South 
Korea) may be limited by the quality of images generated, a problem likely to be addressed 
by continuing technological advances. Single-fiber endoscopy is smaller in diameter (1.6 
mm) compared with TNE and allows for NBI imaging but does not provide operator control 
or the ability to collect biopsy samples [50].
There are also non-endoscopic screening devices for BE that are designed to obtain tissue 
for histologic evaluation. The Cytosponge is a gelatin-coated sponge attached to a string and 
collects cytologic specimens from the esophageal mucosa when withdrawn and may have 
the potential to replace traditional endoscopic screening in a cost-effective manner [51]. 
Preliminary data showed a sensitivity of 73% to 90% for identifying BE when used in 
combination with immunohistochemistry staining for trefoil factor 3 (TFF3) [4], but the 
diagnostic accuracy is still being validated.
Esophageal capsule endoscopy (ECE), another non-invasive capsule device, has shown 
conflicting data as to effectiveness in BE diagnosis [52–54] without being more cost-
effective [55] and, as a result, is not commonly used for screening. Tethered capsule 
endomicroscopy (TCE) can provide additional information regarding the microscopic 
features and architecture of the esophageal wall, and is currently being investigated [50].
Surveillance
Surveillance in BE is aimed at early detection of dysplasia. Dysplasia is categorized as 
NDBE, indeterminate, LGD, HGD, or carcinoma [56]. The presence of dysplasia should be 
confirmed by a second pathologist expert in GI histopathology, due to a high degree of inter-
observer variability [56]. The degree of dysplasia dictates recommended surveillance 
intervals. Patients with NDBE are recommended to have a repeat endoscopy in 3 to 5 years, 
and those with indeterminate dysplasia are recommended to undergo a repeat examination in 
3 to 6 months after optimization of proton pump inhibitor therapy [8]. Patients with LGD 
can undergo eradication therapy, although ongoing endoscopic surveillance is an acceptable 
alternative for LGD. Those with a higher degree of dysplasia should be considered for 
endoscopic eradication therapy (Figure 1).
Careful endoscopic examination of esophageal mucosa and obtaining an adequate number of 
biopsy samples is vital for effective surveillance [57, 58]. Longer mucosal inspection time 
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has been associated with increased detection of HGD/EAC [59]. In addition, highly 
dysplastic lesions in BE are more often found in the right side of the esophagus, so particular 
attention to this area maybe beneficial [60–63]. A standardized biopsy protocol for 
surveillance includes random 4-quadrant biopsies every 2 cm in NDBE and every 1 cm in 
dysplastic BE [64], in addition to targeted sampling of focal mucosal abnormalities. Any 
mucosal abnormalities noted on surveillance should be sampled; among those with a history 
of dysplasia, endoscopic mucosal resection (EMR) is recommended for optimal disease 
staging [65]. Empiric data demonstrate that in current practice, a majority of patients often 
do not undergo adequate biopsies when surveillance is performed leading to decreased 
dysplasia detection [66].
A variety of endoscopic imaging techniques have been developed to improve visualization of 
the esophageal mucosa for detection of dysplasia and neoplasia, although none has been 
adopted for wide-scale routine use presently (Table 1). The current criterion standard for 
both screening and surveillance is use of high-resolution white-light endoscopy (HD-WLE). 
NBI increases detection of dysplasia when compared with HD-WLE and also requires a 
lower number of biopsies [67, 68]. In addition, the type and regularity of mucosal and 
vascular patterns using narrow-band imaging (NBI) have recently been shown to identify 
dysplasia in BE patients with 80% sensitivity and 88% specificity using a new validated NBI 
classification system [69] (Figure 2). Autofluorescence imaging (AFI) can detect mucosal 
abnormalities with high sensitivity but poor specificity compared with HD-WLE [70]. In one 
prospective study, despite using tri-modal imaging with HD-WLE, NBI, and AFI, 10% of 
patients had advanced lesions that were not visibly apparent and were only detected on 
random biopsies [71]. Magnifying endoscopy with chromoendoscopy has been shown to 
improve detection of both IM and dysplasia by enhancing mucosal visibility [72–76]. 
Confocal laser endomicroscopy (CLE) can increase the yield of dysplasia detection [77–79] 
with good accuracy [80, 81] compared with random biopsies but is limited by longer 
procedure times, cost, and the restricted time for mucosal inspection before the injected 
fluorescein dye obscures visualization. Unlike CLE, modalities such as VLE can image a 
larger surface area in a short period of time and can identify sub-squamous BE [82], making 
it a potentially useful tool for surveillance. However, other than case reports and series [83, 
84], VLE’s role and efficacy in BE surveillance is not completely elucidated.
Whether these advanced imaging techniques may obviate the need for random esophageal 
biopsies is a matter of great interest. The “Imaging in Barrett’s Esophagus Preservation and 
Incorporation of Valuable Endoscopic Innovations (PIVI)” initiative [85] by ASGE, 
established minimum performance thresholds for an imaging modality with targeted 
biopsies to replace the need for random biopsies in BE. To meet PIVI performance 
thresholds, an imaging technology in combination with targeted biopsies should have a 
sensitivity of ≥90% and negative predictive value (NPV) of ≥98% for detection of HGD/
EAC, and a specificity of 80% to replace random biopsy protocol. Acetic acid 
chromoendoscopy, NBI, and endoscope-based CLE currently meet these criteria for BE 
surveillance and are endorsed by ASGE for use in surveillance of NDBE by experienced 
operators to obtain targeted biopsies [86].
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Surveillance has been shown to be beneficial in identifying EAC at earlier stages and in 
improving mortality in several retrospective studies [33, 87–89]. However, these studies are 
susceptible to lead-time and length-time biases. Given differences in growth rates between 
tumors, it is quite possible that only the most indolent disease is detected by surveillance 
endoscopy. Consistent with concerns about over-estimation of the effectiveness of 
surveillance, no survival benefit from surveillance was noted in a case–control study from 
the Northern California Kaiser Permanente population [90] or in the US Veterans Health 
Administration [91]. Even if surveillance is effective, the cost-effectiveness of this 
intervention has been questioned [92, 93]. Of note, all these studies focus on survival benefit 
after EAC diagnosis in those undergoing surveillance and do not assess the benefit of 
preventing EAC from endoscopic eradication of dysplasia. Given that recent guidelines 
suggest endoscopic therapy before the development of EAC [8, 94, 95], the impact of 
intervention in dysplastic disease may be under-appreciated. Therefore, despite conflicting 
evidence on the effectiveness of surveillance, it is a recommended practice in the 
management of BE [8].
Current surveillance strategies based on histologic tissue analysis are not without limitations. 
There is evidence that a meaningful proportion of BE patients in a surveillance program can 
progress to EAC despite having no history of dysplasia [87, 96], highlighting the limitations 
of current surveillance in accurately risk-stratifying individuals. Several potential sources of 
error include lack of adherence to recommended biopsy protocol, sampling error, and 
interobserver variability between pathologists of degree of dysplasia [25, 27, 43, 97]. As a 
result, adjunct techniques to improve risk-stratification, such as WATS [41] with computer-
aided analysis to overcome limitations with sampling error, as well as biomarkers, have been 
explored. Although early data on this technology suggest that its use adjunctive to standard 
biopsy protocols might increase detection of dysplasia, its operating characteristics are not 
completely defined, and its application adds time and expense to the procedure.
Molecular biomarkers have been investigated to identify individuals with BE who are at an 
increased risk of progressing to EAC (Table 2). Because BE is thought to develop from a 
dysplasia to carcinoma sequence, the degree of genetic aberration can be used to predict 
disease progression [98]. Molecular abnormalities such as chromosomal aneuploidy or 
tetraploidy, hypermethylation of p16, loss of heterozygosity of p53, and microRNA 
expression, among others, have been associated with progression to HGD or EAC [99–104]. 
Panels of markers have also been tested to increase the predictive ability carcinogenesis 
[105]. All these markers are based on histologic tissue and thus cannot overcome the 
limitation of sampling error. Therefore, attempts have been made to develop serum 
biomarkers, including interleukins, EAC-specific proteins, and serum microRNAs with 
mixed results [38, 106, 107]. To date, none of these markers are routinely used in BE risk-
stratification with the exception of immunohistochemical testing of p53, which is 
recommended by the British Society of Gastroenterology Guidelines (BSG) as an adjunct to 
analysis of biopsy samples during BE surveillance [21].
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MANAGEMENT
Chemoprevention
The utility of chemopreventive agents in BE is unclear. Because those with baseline 
dysplasia are often treated with endoscopic ablation and those with NDBE have a very low 
risk of progression, the safety and cost-effectiveness of long-term use of any agent for 
chemoprevention needs to be justified. Currently, it is recommended that all patients with 
BE, regardless of the presence of GERD symptoms, be treated with once daily PPI based on 
evidence [108] that progression to neoplasia is reduced compared with no PPI therapy or 
with the use of H2 receptor blockers. Although the use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) is associated with a diminished incidence of EAC [109], and a reduced the 
risk of progression to EAC in BE patients by up to 30% [110], the bleeding risk associated 
with NSAIDs may outweigh these benefits and, therefore, they are not currently 
recommended as a chemopreventive strategy in BE [8].
Endoscopic Therapy
Once the diagnosis of BE is confirmed, further management is dictated by the degree of 
dysplasia (Figure 2). In HGD, endoscopic eradication therapy appears to be associated with 
a decreased risk of subsequent adenocarcinoma compared with surveillance endoscopy, and 
may have a similar all-cause mortality rate when compared with esophagectomy [111, 112]. 
There is also evidence [16] that treating LGD [14] with endoscopic eradication therapy 
results in a lower rate of progression to HGD or EAC during a 3-year follow-up period. 
Currently there are differences among professional society guidelines regarding management 
of BE with LGD. Although the ACG and AGA recommend consideration of endoscopic 
eradication therapy for LGD confirmed by a second pathologist, the BSG suggests 
endoscopic surveillance [8, 21, 95]. At this time, routine endoscopic eradication therapy is 
not recommended for NDBE, given the low risk of progression to neoplasia [113], the small 
but real risk of procedure-related adverse events, and the costs inherent in the procedures 
[114, 115]. In general, before initiating treatment, overall patient health, including other 
comorbidities, need to be considered, particularly in those with LGD, where the rates of 
progression to EAC are low.
There are multiple endoscopic therapies available for BE eradication, including resection 
and ablation modalities. The presence of irregular, raised or nodular esophageal mucosa 
within BE is associated with higher rates of malignancy [116], so initial resection of these 
areas with either EMR or endoscopic submucosal dissection (ESD) [117, 118] is necessary 
to determine depth of invasion for staging and selection of further therapy [119]. EMR can 
be performed by band ligation technique or with an endoscopic resection cap and the use of 
a snare for resection. Both techniques are comparable, but in a head to head comparison, 
band ligation was found to be less costly, more time effective, and with fewer adverse events 
[120]. Compared with EMR, ESD offers a more controlled and precise resection of the 
target area and, for larger lesions, determination of adequacy of resection at the lateral 
margins. In general, because the deep margin of the resection is the most important clinically 
actionable data from mucosal resection, and because most centers see small volumes of 
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subjects needing ESD, for most Western endoscopists, the focus should be on performing 
quality EMR.
If the resected nodular area shows LGD, HGD, or T1a EAC without lymphatic or vascular 
involvement, then subsequent endoscopic ablative therapy is recommended [8] for complete 
eradication of IM (CEIM). Although stepwise, radical complete EMR of the entire BE 
segment demonstrates high rates of eradication and remission over a 2-year follow-up period 
[121, 122], stricture rates are demonstrably higher than focal EMR followed by 
radiofrequency ablation (RFA) [123]. Therefore, combination therapy with EMR followed 
by ablation is the recommended approach for most patients, and has been shown to eradicate 
HGD in 86% to 92% of the cases and IM in 62% to 87% of cases [124, 125]. Adverse events 
of endoscopic resection techniques include bleeding, perforation, and a dose-dependent risk 
of stricture formation [121, 122].
For non-nodular BE, several ablative options are available, but RFA is the ablative treatment 
of choice based on efficacy, safety, and availability of a large amount of high-quality data. 
Radiofrequency energy can be delivered either circumferentially through balloon-based 
devices or focally through devices attached to the end of the endoscope (Figure 3). RFA is 
highly effective in eradicating dysplasia in BE patients with 81% of HGD and 91% of LGD 
achieving complete eradication of dysplasia (CED) at 12 months in a multicenter US 
randomized controlled trial [111]. The most common adverse events of RFA is post-ablation 
stricture with a pooled estimate of 5.6% (95% CI, 4.2%–7.4%) [126]. Other rare adverse 
events include bleeding, perforation and post-procedure chest pain requiring hospital 
admission for control.
Cryoablation is another effective ablative modality for management of BE, which delivers 
either liquid nitrogen or carbon dioxide to the intended tissue via a spray catheter inserted 
though the upper endoscope. A newer device is also available to deliver cryotherapy using 
nitrous oxide via a self-contained, balloon based system [127]. Cryoablation can achieve 
complete eradication of HGD in a high proportion of patients with BE in retrospective 
studies, with good durability during a 24-month follow-up period [128, 129]. Similar 
efficacy was seen in prospective data with 81% to 94% eradication of HGD [130, 131]. A 
more recent prospective study showed that cryoablation with pressurized CO2, when 
combined with EMR for treatment of BE with nodular neoplasia provided CED in only 44% 
of the patients [132]. There is a paucity of randomized trials comparing mucosal ablation 
modalities to each other.
Although photodynamic therapy (PDT) is rarely used currently due to cost and side effects, 
level 1 evidence exists for the efficacy of PDT in preventing cancer in BE with HGD [133]. 
In a multicenter study, PDT resulted in eradication of HGD in 77% of the cases with 
maintenance of remission in 85% during a 5-year follow-up period [133, 134]. Despite this 
efficacy, use of PDT is limited by high rates of post-ablation strictures with reports as high 
as 36% and higher procedural cost compared with RFA [134, 135]. Other ablative modalities 
that are available are argon plasma coagulation (APC) and multipolar electrocoagulation, 
which have been shown to have similar rates of CEIM [136]. The most frequent use of APC 
is to treat residual disease after ablation as this can promote sustained remission for a greater 
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duration after CEIM [137]. Although no head to head comparisons exist, APC has been 
shown to have similar cost efficacy to RFA [93].
After CEIM, the risk of recurrence of intestinal metaplasia is significant, especially with risk 
factors such as increasing age, BE segment length, and baseline dysplasia [138] (Figure 4). 
A recent meta-analysis [139] that assessed all types of endoscopic eradication modalities 
showed that the annual incidence of recurrent IM was 7.1%, of dysplastic BE was 1.3%, and 
of HGD/EAC was 0.8%, over more than 10000 patient years of follow-up time. When the 
analysis was restricted to only treatments with RFA, the annual incidence of recurrent IM 
was 9.5%, of dysplastic BE was 2%, and of HGD/EAC was 1.2%. There was a similar risk 
of recurrence in those treated with combination therapy with EMR followed by ablation 
[140]. Although the recurrence of dysplasia is low, it is not insignificant, and thus it is 
important for patients who have achieved CEIM and CED to undergo periodic post-ablation 
surveillance with careful mucosal inspection and both targeted and random biopsies.
Recent work suggests that the highest yield for random biopsies is at the squamocolumnar 
junction, and that strategies that heavily sample that area might improve the yield of 
dysplasia without incurring more biopsies or extra costs [141]. The frequency of current 
surveillance examinations is based on baseline pathology and expert opinion [8]. For 
patients treated for baseline LGD, one commonly used strategy is to perform surveillance 
every 6 months for the first year after CEIM, then annually after. For patients treated with 
baseline HGD, surveillance can be performed every 3 months in the first year after CEIM, 
every 6 months in the second year after CEIM, and then annually after. Recurrent disease is 
treated in a similar manner as before initial endoscopic therapy, and success rates of a 
second CEIM after recurrence of BE are high [138, 142].
Surgical Therapy
Anti-reflux surgery has not been shown to be superior to medical therapy in preventing EAC 
incidence in BE patients based on 2 meta-analyses [143, 144] and is not recommended for 
prevention of neoplasia in BE. There is some evidence that post-ablation the neosquamous 
epithelium is potentially more prone to reflux injury [145], possibly increasing the risk of 
BE recurrence. A recent study found decreased BE recurrence after RFA with Nissen 
fundoplication versus PPI therapy, in the subgroup of patients with long-segment BE and a 
hiatal hernia >3 cm [146]. However, current data as to any incremental benefit of a surgical 
anti-reflux procedure compared with medical therapy after successful RFA remains 
inconclusive [147, 148], and in general the indications for consideration of fundoplication 
after RFA remain similar to those in the general GERD population.
The utility of surgery, specifically esophagectomy, is more evident in BE patients with 
advanced neoplasia. In patients with T1a esophageal adenocarcinoma, esophagectomy may 
be indicated in cases with poorly differentiated tumors, lymphovascular invasion, or cases in 
which ablation is technically difficult or failed [149]. Traditionally, esophagectomy has been 
viewed as the standard of care for all patients with T1b esophageal adenocarcinoma. 
However, the relative merits of esophagectomy and endoscopic therapy in tumors only 
superficially invasive into the submucosa (T1b sm1) have recently come into question. 
Although any submucosal invasion has traditionally been considered to be associated with 
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prohibitively high rates of lymph node involvement to consider endoscopic therapy, recent 
data suggest that at least a subgroup of such patients may be effectively treated 
endoscopically [117]. Currently, the precise degree of tumor invasion to preclude endoscopic 
therapy in a good surgical candidate is unsettled, and data to support endoscopic 
management of patients with tumors showing superficial submucosal invasion is not yet 
robust enough to allow definitive conclusions to be drawn.
CONCLUSION
Although only a small proportion of patients with BE develop EAC, the high mortality and 
cost associated with this outcome drives screening, surveillance, and treatment practices of 
BE, with the ultimate goal of preventing advanced neoplasia. Despite the technical advances 
in detection of metaplasia and neoplasia, the incidence of EAC is rising, highlighting 
inadequacies in current screening and surveillance practices. Because the risk factors of BE 
and EAC extend beyond a history of GERD symptoms, developing cost-effective screening 
tools to identify those at risk is imperative. Once individuals with BE are identified, the goal 
is to prevent progression to EAC through early dysplasia detection and treatment. This must 
involve better risk stratification in the large pool of BE patients to understand who is at 
increased risk of progression. The wide range of evolving imaging and therapeutic 
modalities will likely enhance our ability to detect mucosal abnormalities, but detection of 
dysplasia is currently based on histology, which has its limitations. The use of biomarkers 
and risk-stratification models will have utility to identify individuals with BE who are at 
highest risk of progressing to EAC, and this improved risk stratification can help guide 
targeted interventions. In terms of treatment, endoscopic ablation or endoscopic resection is 
efficacious and has an acceptable safety profile for treating BE with early neoplasia. 
Esophagectomy is generally reserved for advanced cases of EAC, and those failing 
endoscopic eradication therapy.
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Acronyms
BE Barrett’s esophagus
GERD gastroesophageal reflux disease
EAC esophageal adenocarcinoma
HGD high-grade dysplasia
LGD low-grade dysplasia
NDBE non-dysplastic Barrett’s esophagus
GE gastroesophageal
IM intestinal metaplasia
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NBI narrow-band imaging
WATS Wide-area transepithelial sampling
TNE transnasal endoscopy
TFF3 trefoil factor 3
ECE Esophageal capsule endoscopy
TCE Tethered capsule endomicroscopy
EMR endoscopic mucosal resection
HD-WLE high-resolution white-light endoscopy
AFI autofluorescence imaging
CLE confocal laser endomicroscopy
PIVI Preservation and Incorporation of Valuable Endoscopic Innovations
NPV negative predictive value
NSAIDs Nonsteroidal anti-inflammatory drugs
BSG British Society of Gastroenterology Guidelines
ESD endoscopic submucosal dissection
RFA radiofrequency ablation
CEIM complete eradication of intestinal metaplasia
CED complete eradication of dysplasia
PDT photodynamic therapy
APC argon plasma coagulation
LOH loss of heterozygosity
FISH fluorescent in-situ hybridization
RR relative risk
CI confidence interval
AUC area under curve
OR odds ratio
BING Barrett’s International NBI Group
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Figure 1. 
Schematic for management of non-nodular Barrett’s esophagus (BE) [8]. Surveillance upper 
endoscopy at 1-year intervals is an acceptable alternative to endoscopic eradication therapy. 
T1a esophageal adenocarcinoma (EAC) is amenable for endoscopic therapy. (Image 
reproduced with permission).
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Figure 2. 
Classification of regular and irregular mucosal and vascular patterns using the validated 
Barrett’s International NBI Group (BING) criteria for detection of high-grade dysplasia and 
esophageal adenocarcinoma using narrow-band imaging (NBI) in Barrett’s esophagus [69]. 
(Image reproduced with permission).
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Figure 3. 
Available radiofrequency ablation devices (RFA) include a circumferential device that can 
be used for ablation of large areas and focal devices comprising a paddle that can either be 
attached to the tip or placed through the working channel of an upper endoscope. (All rights 
reserved. Used with the Permission of Medtronic).
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Figure 4. 
Kaplan-Meier plot of intestinal metaplasia (IM) recurrence among patients (n=1613) who 
achieved complete eradication of intestinal metaplasia (CEIM) after RFA, with pretreatment 
histology non-dysplastic BE (NDBE), low-grade dysplasia (LGD), and high-grade dysplasia 
(HGD) [138]. (Image reproduced with permission).
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